CL H ϭ
Q H,B ⅐ fu ⅐ CLu int,H Q H,B ϩ fu ⅐ CLu int,H /͑C B /C P )
As expected conceptually, eq. 1 indicates that hepatic blood clearance cannot exceed liver blood flow. However, from eq. 2, it is possible that hepatic plasma clearance may exceed hepatic blood flow (and hepatic plasma flow) when fuCLu int,H Ͼ Ͼ Q H,B and C B /C P Ͼ 1 (Hinderling, 1997) . Some confusion over the definition of fu B and a failure to appreciate the conversion between blood and plasma clearance are evident in some of the recent literature, confounding the ability to extrapolate between in vitro and in vivo drug clearance.
The Definition of fu B
The free fraction of drug in blood is given by eq. 3:
where Au B is the amount of unbound drug in whole blood and A B is the total amount of drug in blood. Thus:
where Cu RBC is the unbound drug concentration in cells (essentially red blood cells; RBC); V RBC is the volume of RBC per milliliter of blood; Cu is unbound drug concentration in plasma water; V P is the volume of plasma per milliliter of blood; and Hc is the hematocrit.
In the original development of the well-stirred model, the assumption was made that the unbound concentration of drug in blood cells equates to the unbound concentration in plasma (Cu RBC ϭ Cu). Hence, eq. 4 becomes:
In contrast, Masimirembwa et al. (2003) defined the free fraction in blood as:
However, this only applies where no drug associates with the cells (Cu RBC ϭ 0 in eq. 4) when, to provide a correct value of hepatic blood clearance, eq. 1 would need to be modified to eq. 7:
In the special case of the drug not associating with blood cells at all, it is preferable to report plasma, rather than blood, clearance, using fu and hepatic plasma flow (Q H,B (1 Ϫ Hc)).
Estimation of in Vivo Hepatic Clearance from in Vitro Data
Values of CLu int,H derived using human liver microsomes, hepatocytes, or recombinant enzymes are often scaled to in vivo hepatic clearance using the well-stirred model. However, in deriving hepatic plasma clearance, several recent studies have used eq. 8 instead of the correct form (eq. 2) (Blanchard et al., 2004; Foti and Fisher, 2004; Blanchard et al., 2005; de Graaf et al., 2006; Mohutsky et al., 2006; Strelevitz et al., 2006) :
This would only be valid if C B /C P were equal to unity. For drugs with low values of fuCLu int,H , estimates of CL H would be similar using eqs. 2 and 8. Thus, when fuCLu int,H Ͻ Ͻ Q H,B (eq. 2 and 8), CL H approaches fuCLu int,H , and the factor C B /C P is not important. However, major discrepancies would result for higher clearance drugs when C B /C P does not equal unity.
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org. doi:10.1124/dmd.106.013359.
Estimation of Intrinsic Hepatic Clearance from in Vivo Data
To assess predictions of intrinsic hepatic drug clearance from in vitro data, estimates are often compared with values back-calculated from in vivo values of hepatic drug clearance using the well-stirred model. In this context, studies (e.g., Takanaga et al., 2000) have employed eq. 9 by rearranging eq. 8, instead of the correct form (eq. 10 from a rearrangement of eq. 2):
Estimation of Hepatic Availability from in Vivo Data
Another common application of the well-stirred model is to estimate the fraction avoiding "first-pass" metabolism (hepatic availability; F H ) after oral drug administration from systemic clearance after intravenous administration. Assuming negligible extrahepatic clearance, several reports have used plasma drug clearance after intravenous administration (CL iv ) and eq. 11 (Lau et al., 2006; Strelevitz et al., 2006) or eq. 12 (Kharasch et al., 2004a,b) to estimate F H :
Eq. 11 is only valid if C B /C P is unity, and eq. 12 is not valid unless C B /C P is equal to (1 Ϫ Hc) (i.e., no drug associates with the cells). A more appropriate equation, based on the original assumptions of the well-stirred model, is given by eq. 13:
The different implications of eqs. 11 through 13 for the estimation of F H are explored in Fig. 1 .
Errors in the estimation of F H may be further propagated into estimates of the fraction avoiding first-pass loss across the gut wall (F G ) from the relationship F/(faF H ), where F is net oral bioavailability and fa is the fraction of the dose entering the intestinal wall (Takanaga et al., 2000; Kharasch et al., 2004a,b) .
In summary, we emphasize that the mixing of plasma free fraction and hepatic blood flow is inadvisable and illogical when using the well stirred liver, or indeed any model of hepatic drug clearance, for in vitro/in vivo extrapolation. 
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